Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Use of aspirin associates with longer primary patency of hemodialysis grafts.

Dixon BS, Beck GJ, Dember LM, Vazquez MA, Greenberg A, Delmez JA, Allon M, Himmelfarb J, Hu B, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Lawson JH, Cotton JR Jr, Kusek JW, Feldman HI; Dialysis Access Consortium (DAC) Study Group..

J Am Soc Nephrol. 2011 Apr;22(4):773-81. doi: 10.1681/ASN.2010060582. Epub 2011 Mar 17.

2.

Effect of dipyridamole plus aspirin on hemodialysis graft patency.

Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI; DAC Study Group..

N Engl J Med. 2009 May 21;360(21):2191-201. doi: 10.1056/NEJMoa0805840.

3.

Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.

Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH.

Cochrane Database Syst Rev. 2015 Feb 19;(2):CD000535. doi: 10.1002/14651858.CD000535.pub3. Review.

PMID:
25695213
4.

Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial.

Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, Himmelfarb J, Hunsicker LG, Kaufman JS, Lawson JH, Meyers CM, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI; DAC Study Group..

Clin Trials. 2005;2(5):400-12.

PMID:
16317809
5.

Aspirin and arteriovenous graft thrombosis in hemodialysis: just what the doctor ordered?

Bech FR, Chertow GM.

J Am Soc Nephrol. 2011 Apr;22(4):595-7. doi: 10.1681/ASN.2011020181. Epub 2011 Mar 17. No abstract available.

7.

Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.

Irish A, Dogra G, Mori T, Beller E, Heritier S, Hawley C, Kerr P, Robertson A, Rosman J, Paul-Brent PA, Starfield M, Polkinghorne K, Cass A.

BMC Nephrol. 2009 Jan 21;10:1. doi: 10.1186/1471-2369-10-1.

8.

Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the dialysis outcomes and practice patterns study.

Hasegawa T, Elder SJ, Bragg-Gresham JL, Pisoni RL, Yamazaki S, Akizawa T, Jadoul M, Hugh RC, Port FK, Fukuhara S.

Clin J Am Soc Nephrol. 2008 Sep;3(5):1373-8. doi: 10.2215/CJN.00130108. Epub 2008 Jul 2.

9.

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.

Osborn G, Escofet X, Da Silva A.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD002786. doi: 10.1002/14651858.CD002786.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;7:CD002786.

PMID:
18843633
10.

The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts.

Farber A, Tan TW, Hu B, Dember LM, Beck GJ, Dixon BS, Kusek JW, Feldman HI; Dialysis Access Consortium (DAC) Study Group.; Dialysis Access Consortium DAC Study Group..

J Vasc Surg. 2015 Nov;62(5):1258-64. doi: 10.1016/j.jvs.2015.06.132. Epub 2015 Aug 6.

PMID:
26254823
11.

Angiotensin receptor blockers and antiplatelet agents are associated with improved primary patency after arteriovenous hemodialysis access placement.

Jackson RS, Sidawy AN, Amdur RL, Khetarpal A, Macsata RA.

J Vasc Surg. 2011 Dec;54(6):1706-12. doi: 10.1016/j.jvs.2011.06.028. Epub 2011 Aug 15.

12.

Patency in arteriovenous grafts in hemodialysis patients.

Mousa AY, Patterson W, Abu-Halimah S, Hass SM, Alhalbouni S, Sadek BT, Nanjundappa A, Modak A, Stone PA, Emmett M, AbuRahma AF.

Vasc Endovascular Surg. 2013 Aug;47(6):438-43. doi: 10.1177/1538574413493678. Epub 2013 Jul 12.

PMID:
23853221
13.

Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study.

Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM.

Kidney Int. 1994 May;45(5):1477-83.

14.

Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW; Dialysis Outcomes and Practice Patterns Study..

Am J Kidney Dis. 2002 Dec;40(6):1255-63.

PMID:
12460045
15.

Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft.

Nee R, Parker AL, Little DJ, Yuan CM, Himmelfarb J, Lowe SR, Abbott KC.

Clin Nephrol. 2014 Jan;81(1):38-51. doi: 10.5414/CN108100.

PMID:
24161074
16.

Heparin bonding does not improve patency of polytetrafluoroethylene arteriovenous grafts.

Allemang MT, Schmotzer B, Wong VL, Chang A, Lakin RO, Woodside KJ, Wang J, Kashyap VS.

Ann Vasc Surg. 2014 Jan;28(1):28-34. doi: 10.1016/j.avsg.2013.08.001. Epub 2013 Nov 5.

PMID:
24200142
17.

Dipyridamole plus aspirin and hemodialysis graft patency.

Weale AR, Cooper DG.

N Engl J Med. 2009 Aug 13;361(7):720; author reply 721. doi: 10.1056/NEJMc091312. No abstract available.

18.

Dipyridamole plus aspirin and hemodialysis graft patency.

Hentschel DM.

N Engl J Med. 2009 Aug 13;361(7):720-1; author reply 721. No abstract available.

PMID:
19681176
19.

Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.

Belch JJ, Dormandy J; CASPAR Writing Committee., Biasi GM, Cairols M, Diehm C, Eikelboom B, Golledge J, Jawien A, Lepäntalo M, Norgren L, Hiatt WR, Becquemin JP, Bergqvist D, Clement D, Baumgartner I, Minar E, Stonebridge P, Vermassen F, Matyas L, Leizorovicz A.

J Vasc Surg. 2010 Oct;52(4):825-33, 833.e1-2. doi: 10.1016/j.jvs.2010.04.027. Epub 2010 Aug 1. Erratum in: J Vasc Surg. 2011 Feb;53(2):564. Biasi, B M [corrected to Biasi, G M].

20.

Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial.

McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh R.

J Vasc Surg. 1991 Jan;13(1):150-61; discussion 161-2.

PMID:
1987387

Supplemental Content

Support Center